Regenera receives ethics approval for second clinical trial
By Renate Krelle
Wednesday, 20 October, 2004
Wednesday, 20 October, 2004
Perth's Regenera (ASX: RGA) has received ethics approval for the second of five Phase III clinical trial to be conducted in Singapore using intravitreal injections of its product Visagen to treat macular oedema.
Visagen is a preservative free formulation of the steroid triamcinolone acetonide.
The trials will be conducted in conjunction with the Singapore Eye Research Institute, an arm of the Singapore National Eye Centre.
Related News
New route into cells found for gene therapy viruses
Scientists have identified a previously unknown gateway into human cells — a receptor...
Link between oestrogen and heart health found in women
Scientists found that oestrogen helps increase the ANXA1 protein, and when ANXA1 is missing, the...
Frequent nightmares accelerate aging, increase risk of death
Nghtmares independently predict faster biological aging and earlier mortality — even after...
